Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000318008 | SCV000340589 | uncertain significance | not provided | 2016-03-24 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001080275 | SCV000766021 | benign | Tuberous sclerosis 2 | 2024-01-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000318008 | SCV001940282 | likely benign | not provided | 2020-05-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001080275 | SCV002039578 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002257626 | SCV002531004 | benign | Hereditary cancer-predisposing syndrome | 2022-01-05 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002257626 | SCV002711050 | likely benign | Hereditary cancer-predisposing syndrome | 2019-12-18 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |